Skip to main content
Premium Trial:

Request an Annual Quote

BD Diagnostics Gets FDA Clearance for Second BD Max Staph Assay

NEW YORK (GenomeWeb News) — BD Diagnostics, a segment of Becton Dickinson, said today that it has received US Food and Drug Administration clearance to market its BD Max MRSA XT assay for use on the BD Max system.

This is the second assay from BD Diagnostics capable of detecting newly emerging methicillin-resistant Staphylococcus aureus strains with the novel mecC gene. The company's BD Max StaphSR assay for use on the BD Max system received FDA clearance in December.

Both assays use BD's "eXTended" detection technology to identify a broad range of S. aureus strains including mecA and mecC dropout mutants and new strains of MRSA, the company said.

However, the new BD Max MRSA XT provides a single actionable result — positive of negative for MRSA — whereas StaphSR provides two actionable results — positive or negative for S. aureus and for MRSA, according to a spokesperson.

In addition, the spokesperson said that BD Max MRSA ST is intended for use in active surveillance programs to help hospitals accurately identify patients colonized with MRSA, while StaphSR is intended to be used in pre-surgical screening to identify patients colonized with S. aureus or MRSA.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.